Response to comment on “Pembrolizumab in advanced endometrial cancer: Dosing equivalence and molecular insights from an Asian cohort”

Journal of the Formosan Medical Association · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles